A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors

被引：5
|
作者：
Wang-Gillam, Andrea [1 ]
Tew, William P. [2 ]
Rothenberg, Mace L. [3 ,5 ]
Dupont, Jakob [2 ]
Cooper, Wendy [3 ]
Sternas, Lars [4 ]
Buzenet, Giliane [4 ]
Sosman, Jeffrey A. [3 ]
Spriggs, David R. [2 ]
Lockhart, Albert Craig [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[4] Sanofi Aventis Oncol, Bridgewater, NJ USA
[5] Pfizer Inc, New York, NY USA
来源：
INVESTIGATIONAL NEW DRUGS | 2012年 / 30卷 / 05期
关键词：
Phase I study; Aflibercept; Angiogenesis inhibitor; Subcutaneously administration; GROWTH-FACTOR-TRAP; ASCITES;
D O I：
10.1007/s10637-011-9753-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors. This phase I study was to evaluate a new formulation of subcutaneously administered aflibercept in patients with advanced solid tumors. Here we report our experience with the toxicity, pharmacokinetic profile and efficacy of the new 100 mg/mL subcutaneous (SC) formulation of aflibercept administered at a dose of at 4 mg/kg every 2 weeks.
引用
收藏
页码：1958 / 1961
页数：4
相关论文
共 50 条
  • [1] A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
    Andrea Wang-Gillam
    William P. Tew
    Mace L. Rothenberg
    Jakob Dupont
    Wendy Cooper
    Lars Sternas
    Giliane Buzenet
    Jeffrey A. Sosman
    David R. Spriggs
    Albert Craig Lockhart
    Investigational New Drugs, 2012, 30 : 1958 - 1961
  • [2] A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    Diaz-Padilla, I.
    Siu, L. L.
    San Pedro-Salcedo, M.
    Razak, A. R. A.
    Colevas, A. D.
    Shepherd, F. A.
    Leighl, N. B.
    Neal, J. W.
    Thibault, A.
    Liu, L.
    Lisano, J.
    Gao, B.
    Lawson, E. B.
    Wakelee, H. A.
    BRITISH JOURNAL OF CANCER, 2012, 107 (04) : 604 - 611
  • [3] A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
    I Diaz-Padilla
    L L Siu
    M San Pedro-Salcedo
    A R A Razak
    A D Colevas
    F A Shepherd
    N B Leighl
    J W Neal
    A Thibault
    L Liu
    J Lisano
    B Gao
    E B Lawson
    H A Wakelee
    British Journal of Cancer, 2012, 107 : 604 - 611
  • [4] Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
    Sunakawa, Yu
    Takahashi, Keishiro
    Kawaguchi, Osamu
    Yamamoto, Nobuyuki
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1032 - 1041
  • [5] Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours
    Van Cutsem, Eric
    Khayat, David
    Verslype, Chris
    Billemont, Bertrand
    Tejpar, Sabine
    Meric, Jean-Baptiste
    Soussan-Lazard, Karen
    Assadourian, Sylvie
    Cartot-Cotton, Sylvaine
    Rixe, Olivier
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 17 - 24
  • [6] Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies
    Yu Sunakawa
    Keishiro Takahashi
    Osamu Kawaguchi
    Nobuyuki Yamamoto
    Investigational New Drugs, 2022, 40 : 1032 - 1041
  • [7] Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: Results from the expansion cohort of a phase I study
    Khayat, David
    Tejpar, Sabine
    Spano, Jean-Philippe
    Verslype, Chris
    Bloch, Joel
    Vandecaveye, Vincent
    Assadourian, Sylvie
    Soussan-Lazard, Karen
    Cartot-Coton, Sylvaine
    Van Cutsem, Eric
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (04) : 790 - 797
  • [8] Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
    Toshio Shimizu
    Kazuhiko Nakagawa
    Hidetoshi Hayashi
    Tsutomu Iwasa
    Hisato Kawakami
    Satomi Watanabe
    Noboru Yamamoto
    Kan Yonemori
    Takafumi Koyama
    Jun Sato
    Kenji Tamura
    Keiichi Kikuchi
    Kenichiro Akaike
    Shiho Takeda
    Masayuki Takeda
    Investigational New Drugs, 2023, 41 : 1 - 12
  • [9] Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study
    Shimizu, Toshio
    Nakagawa, Kazuhiko
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Kawakami, Hisato
    Watanabe, Satomi
    Yamamoto, Noboru
    Yonemori, Kan
    Koyama, Takafumi
    Sato, Jun
    Tamura, Kenji
    Kikuchi, Keiichi
    Akaike, Kenichiro
    Takeda, Shiho
    Takeda, Masayuki
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (01) : 1 - 12
  • [10] Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
    Okamoto, Isamu
    Doi, Toshihiko
    Ohtsu, Atsushi
    Miyazaki, Masaki
    Tsuya, Asuka
    Kurei, Katsutoshi
    Kobayashi, Ken
    Nakagawa, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (01) : 17 - 23
12345